Problem

Adialante targets the access and delay problem in diagnostic MRI. Conventional scanners cost millions, take months to install, require specialized infrastructure, and are concentrated in hospitals, leaving many clinics unable to offer MRI and creating weeks-long waits. The clinical and economic pain is especially acute in prostate cancer: more than one million men each year require an MRI before prostate biopsy, yet most urology practices cannot provide the scan in-house. Delayed imaging can mean delayed diagnosis, while clinics lose the opportunity to retain the referral and associated reimbursement.

Product / Service

Adialante is developing compact, diagnostic-grade whole-body MRI systems delivered as a mobile imaging clinic. Rather than selling the equipment, it plans to own and operate MRI units in trailers, bring them to medical practices, manage scanning operations, and improve the system’s AI software over time. The system is designed to use substantially less hardware, be lighter, quieter, shorter, and require no specialized infrastructure.

Clinics pay a flat per-scan fee instead of making a multimillion-dollar capital purchase or undertaking construction. They schedule patients on-site, collect the insurance reimbursement, and retain the margin, while patients can receive imaging in hours rather than being referred to a hospital and waiting months. Adialante’s initial use case is pre-biopsy prostate imaging, with planned expansion into renal, breast, and brain scanning.

Market

Adialante competes in portable and mobile diagnostic MRI, with an initial focus on decentralized cancer screening and point-of-care imaging. Its closest differentiated competitors include Hyperfine, whose FDA-cleared Swoop system is a portable brain MRI, and Promaxo, whose FDA-cleared platform focuses on MRI-guided prostate procedures. Adialante’s intended distinction is a mobile, diagnostic-grade, whole-body platform operated as a service rather than a scanner sold to each clinic; conventional hospital MRI remains the incumbent alternative.

The company is an early commercial-stage medtech startup rather than an established revenue business. Its public materials say first clinics are planned to go live in Q4 2026, while also reporting that a first system is scanning. By July 2026, Adialante reported 11 clinics reserving slots and $19.75 million in signed letters of intent, alongside deposits from early customers; the cited materials do not report recognized revenue. The commitments indicate meaningful demand validation, but deployment, regulatory commercialization, utilization, and recurring revenue remain ahead of the company.